11.01.03
Results of a new pilot study funded by the National Institutes of Health (NIH) showed that daily supplementation with 1000 mcg of chromium picolinate significantly enhanced insulin sensitivity. These initial results offer a potential new nutritional therapy for approximately 2 million American women suffering from Polycystic Ovarian Syndrome (PCOS). PCOS is a little understood hormonal condition that is a leading cause of infertility and is associated with insulin resistance, gestational diabetes and type 2 diabetes. In an effort to build on limited PCOS treatment options, researchers at the State University of New York (SUNY), Stony Brook, analyzed the effects of nutritional supplementation with chromium in the form of Chromax® chromium picolinate, which is marketed by Nutrition 21, on six women with PCOS. Results showed that glucose disposal rate (insulin sensitivity) was significantly increased by an average of 35% after two months of treatment and baseline insulin levels decreased by 22%.